[{"id":"72d8c724-8d53-4e69-afd5-a79ba1831075","acronym":"REMAIN","url":"https://clinicaltrials.gov/study/NCT06029270","created_at":"2023-09-08T20:10:10.653Z","updated_at":"2025-02-25T13:55:33.082Z","phase":"Phase 2","brief_title":"Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer","source_id_and_acronym":"NCT06029270 - REMAIN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 07/15/2024","start_date":" 07/15/2024","primary_txt":" Primary completion: 04/30/2029","primary_completion_date":" 04/30/2029","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-02-20"},{"id":"6b56b2f0-6f31-45d1-8ab6-6477c5f17c19","acronym":"RELATIVITY-1093","url":"https://clinicaltrials.gov/study/NCT06561386","created_at":"2025-02-25T14:04:42.242Z","updated_at":"2025-02-25T14:04:42.242Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","source_id_and_acronym":"NCT06561386 - RELATIVITY-1093","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/07/2024","start_date":" 10/07/2024","primary_txt":" Primary completion: 07/30/2030","primary_completion_date":" 07/30/2030","study_txt":" Completion: 11/11/2033","study_completion_date":" 11/11/2033","last_update_posted":"2025-02-19"},{"id":"b2796697-f53f-4b0f-891f-ff27bfd09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05852691","created_at":"2023-05-10T21:04:00.257Z","updated_at":"2025-02-25T14:09:43.602Z","phase":"Phase 2","brief_title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05852691","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • ER • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2 • PD-L1 • ER • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"acb735f2-e0d3-48ef-9323-330de9633b97","acronym":"BGB-900-102","url":"https://clinicaltrials.gov/study/NCT03744468","created_at":"2021-01-18T18:20:22.768Z","updated_at":"2025-02-25T14:40:03.995Z","phase":"Phase 1/2","brief_title":"Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT03744468 - BGB-900-102","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-14"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"29c36fa3-ec25-4585-bc53-d76f48cbd87a","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT06816927","created_at":"2025-02-25T15:46:23.088Z","updated_at":"2025-02-25T15:46:23.088Z","phase":"Phase 2","brief_title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","source_id_and_acronym":"NCT06816927 - GIANT","lead_sponsor":"Duke University","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-10"},{"id":"38d14a85-f7dd-4762-9bf5-4da0e8be0e8f","acronym":"KEYMAKER-U04 Substudy","url":"https://clinicaltrials.gov/study/NCT05845814","created_at":"2023-05-06T15:04:43.804Z","updated_at":"2025-02-25T15:28:00.798Z","phase":"Phase 1/2","brief_title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","source_id_and_acronym":"NCT05845814 - KEYMAKER-U04 Substudy","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-10"},{"id":"5741b2e4-403a-47d5-b489-ab51fac66036","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645692","created_at":"2022-12-09T14:57:54.227Z","updated_at":"2025-02-25T16:39:31.560Z","phase":"Phase 2","brief_title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","source_id_and_acronym":"NCT05645692","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 204","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-06"},{"id":"c54aeb23-834a-4c49-9030-ec1b4fe12e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800015","created_at":"2023-04-05T14:03:34.879Z","updated_at":"2025-02-25T17:26:07.111Z","phase":"Phase 2/3","brief_title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05800015","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 01/16/2030","primary_completion_date":" 01/16/2030","study_txt":" Completion: 12/23/2031","study_completion_date":" 12/23/2031","last_update_posted":"2025-01-31"},{"id":"9e786c9b-5753-46e4-84c2-5d48fa205166","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953104","created_at":"2021-07-07T12:53:55.344Z","updated_at":"2025-02-25T17:37:12.423Z","phase":"Phase 2","brief_title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","source_id_and_acronym":"NCT04953104","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ARID1A • CXCL13","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-29"},{"id":"f63dc019-68d2-4470-a8e6-c78d4c247511","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642067","created_at":"2021-01-18T17:52:44.817Z","updated_at":"2025-02-25T14:27:30.812Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","source_id_and_acronym":"NCT03642067","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/23/2024","primary_completion_date":" 02/23/2024","study_txt":" Completion: 09/18/2024","study_completion_date":" 09/18/2024","last_update_posted":"2025-01-28"},{"id":"a2aa78c5-6c40-4253-8db6-d0f14ce0af71","acronym":"","url":"https://clinicaltrials.gov/study/NCT06769698","created_at":"2025-02-26T07:08:07.434Z","updated_at":"2025-02-26T07:08:07.434Z","phase":"Phase 2","brief_title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06769698","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/26/2025","start_date":" 03/26/2025","primary_txt":" Primary completion: 04/22/2027","primary_completion_date":" 04/22/2027","study_txt":" Completion: 11/28/2029","study_completion_date":" 11/28/2029","last_update_posted":"2025-01-10"},{"id":"72e4ff17-7877-4262-a51d-7d8c81b8c732","acronym":"Neo ReNi II","url":"https://clinicaltrials.gov/study/NCT05418972","created_at":"2022-06-15T16:54:46.563Z","updated_at":"2025-02-25T14:17:02.671Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","source_id_and_acronym":"NCT05418972 - Neo ReNi II","lead_sponsor":"Melanoma Institute Australia","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • NRAS wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2025-01-07"},{"id":"def7c0d3-011b-4e25-936d-9f3f6364ae6a","acronym":"Liberty-201","url":"https://clinicaltrials.gov/study/NCT05609370","created_at":"2022-11-08T14:56:34.793Z","updated_at":"2025-02-25T16:18:17.599Z","phase":"Phase 1/2","brief_title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05609370 - Liberty-201","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • alcestobart (LBL-007)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 01/29/2023","start_date":" 01/29/2023","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-01-01"},{"id":"8a338706-627b-439d-8379-dc445573fb74","acronym":"RELATIVITY-104","url":"https://clinicaltrials.gov/study/NCT04623775","created_at":"2025-02-26T07:17:29.802Z","updated_at":"2025-02-26T07:17:29.802Z","phase":"Phase 2","brief_title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04623775 - RELATIVITY-104","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 468","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2024-12-20"},{"id":"45c046f9-397a-49d4-a98d-7b69753ec117","acronym":"","url":"https://clinicaltrials.gov/study/NCT06295159","created_at":"2024-03-06T20:34:03.944Z","updated_at":"2025-02-25T14:18:50.824Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","source_id_and_acronym":"NCT06295159","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-12-17"},{"id":"aea0f58d-10bb-4911-b89f-8864936129e3","acronym":"CA224-056","url":"https://clinicaltrials.gov/study/NCT04080804","created_at":"2021-01-18T19:58:51.916Z","updated_at":"2025-02-25T14:28:37.614Z","phase":"Phase 2","brief_title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","source_id_and_acronym":"NCT04080804 - CA224-056","lead_sponsor":"Dan Zandberg","biomarkers":" TMB • LAG3","pipe":" | ","alterations":" CD8 positive","tags":["TMB • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-12-13"},{"id":"949b2ac3-8269-489d-a405-99b472b2028a","acronym":"CA209-6D9","url":"https://clinicaltrials.gov/study/NCT05704933","created_at":"2023-01-30T15:59:33.242Z","updated_at":"2025-02-25T14:17:35.071Z","phase":"Phase 1","brief_title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","source_id_and_acronym":"NCT05704933 - CA209-6D9","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • PD-1 • IFNG • CD4 • IL2 • IL10","pipe":" | ","alterations":" PD-1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-09"},{"id":"fa5b6f9e-e872-40f2-bf84-a917001c5d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607890","created_at":"2021-01-17T17:13:23.826Z","updated_at":"2025-02-25T14:27:22.614Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","source_id_and_acronym":"NCT03607890","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/16/2018","start_date":" 11/16/2018","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-23"},{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"4aeea117-34ac-4801-a9a7-3c04faeab1e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05912244","created_at":"2023-06-22T20:09:31.362Z","updated_at":"2025-02-25T16:18:54.885Z","phase":"Phase 2","brief_title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","source_id_and_acronym":"NCT05912244","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 06/09/2027","primary_completion_date":" 06/09/2027","study_txt":" Completion: 06/09/2027","study_completion_date":" 06/09/2027","last_update_posted":"2024-08-16"},{"id":"1d9df858-02f3-4502-906c-15d18a9ed9f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06494943","created_at":"2025-02-26T14:28:07.615Z","updated_at":"2025-02-26T14:28:07.615Z","phase":"Phase 1","brief_title":"Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC","source_id_and_acronym":"NCT06494943","lead_sponsor":"Fudan University","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • negalstobart (IBI110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/26/2024","start_date":" 06/26/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-07-10"},{"id":"2733b16c-4744-4169-8120-2555bfcf29cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867799","created_at":"2021-01-18T19:04:28.946Z","updated_at":"2024-07-02T16:34:26.092Z","phase":"Phase 2","brief_title":"iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","source_id_and_acronym":"NCT03867799","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 10/21/2022","primary_completion_date":" 10/21/2022","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-06-14"},{"id":"91463b97-ebd1-4b46-aa50-28330829d950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05577182","created_at":"2022-10-13T17:58:01.319Z","updated_at":"2024-07-02T16:34:26.137Z","phase":"Phase 1","brief_title":"Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies","source_id_and_acronym":"NCT05577182","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA32459"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-06-14"}]